Saffron in the treatment of postmenopausal hot flash

Phase 3

• Conditions: Hot flashing.; Menopausal and female climacteric states

• Registration Number: IRCT201602031556N85
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 50

Inclusion Criteria

women aged between 45-65 years old; menopause.
Exclusion criteria: moderate to severe post-menopausal hot flushing-five episodes per day from 2 months ago; sopping of the mens from 12 month ago; receiving estrogen or progesterone during the last two months; receiving antidepressants during the last month; receving Selective Estrogen Receptor Modulators including raloxifen and tamoxifen during the last month; receiving aromatase inhibitors such as Anastrozole, Letrozole, Exemestane during the last month;receving Leuprolide acetate during the last month; receiving clonidine during the last month; receving gabapentine and pregabalin during the last month; receiving hot flushing reducing medications during the last month; receiving amino acid supplements during the last month.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of hot flashing. Timepoint: Baseline and 2, 4, 6 weeks after beginnig of treatment. Method of measurement: By Hot flash Related Daily Interference.

Secondary Outcome Measures

Name	Time	Method
Severity of depression. Timepoint: Baseline and 2, 4, 6 weeks after beginnig of treatment. Method of measurement: By Hamilton Depression Rating scale.